Document is current
Any future updates will be listed below
-
Authors
Kamminga, Nadia C.W.
van der Veldt, Astrid A.M.
Wakkee, Marlies
van den Berge, Fauve R.
van der Beek, Lianne A.A.
Joosen, Margot C.W.
Joosse, Arjen
de Joode, Karlijn
Nijsten, Tamar E.C.
Lugtenberg, Marjolein http://orcid.org/0000-0002-4117-2154
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
Merck Sharp and Dohme United Kingdom
Novartis
Les Laboratories Pierre Fabre
- License Information
-
More Information
Article History
Received: 24 April 2024
Accepted: 22 May 2024
First Online: 30 May 2024
Declarations
:
: The study protocol was submitted to, and approved by, the Medical Ethics Committee Erasmus MC. After reviewing the protocol, the committee concluded that the Medical Research Involving Human Subjects Act (Dutch abbreviation: WMO) did not apply to this study (MEC-2019-0558 and MEC-2020-0197). Written informed consent was obtained from all participants involved in the study.
: Not applicable.
: AV: advisory/consultancy (all paid to the institute) for BMS, Eisai, Ipsen, Novartis, MSD, Merck, Pfizer, Pierre Fabre, Roche, Sanofi. All other authors have no conflicts of interest to share.
